GlassScriptPhysician profile
Nagaraja N Patil
NPI 1962592501
$19,846.07
in general payments reported to CMS, 2019-2025
48 companies · $3,625 in 2025
The $3,625 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,073 · 2020: $1,209 · 2021: $2,014 · 2022: $2,279 · 2023: $4,117 · 2024: $3,529 · 2025: $3,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,270.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,906.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $2,370.51 | 2019-2025 | Evenity, Repatha, Repatha |
| Abbvie INC. | $1,680.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,557.19 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,012.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $810.58 | 2019-2024 | Xarelto |
| Pfizer INC. | $769.69 | 2019-2025 | |
| Lilly USA, LLC | $727.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $653.75 | 2021 | |
| Abbott Laboratories | $514.65 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.08 | 2019-2025 | Ofev, Jardiance |
| Exact Sciences Corporation | $442.33 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $409.29 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $383.86 | 2022-2024 | |
| Astellas Pharma US INC | $353.02 | 2022-2025 | Veozah, Myrbetriq |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagaraja Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.